Risk factor
Strong & resilient to price shocks
Profitability factor
Greatly overvalued vs peers
About
Aker BioMarine AS, a subsidiary of Aker ASA, is a Norwegian company established in 2006 and headquartered in Lysaker. The firm is dedicated to the global development, production, and commercialization of ingredients sourced from krill, serving diverse applications in nutraceuticals, dietary supplements, and animal feed. Its market reach extends across Norway, the Americas, Asia Pacific, Europe, the Middle East, and Africa. The company operates through two distinct segments: Ingredients and Brands. Its product portfolio features Superba, a krill-derived nutraceutical ingredient recognized for its phospholipid complex containing choline, omega-3s, and astaxanthin. Other key offerings include QRILL Aqua, designed for aquaculture, and QRILL Pet, tailored for animal feed. Aker BioMarine also provides LYSOVETA, an innovative delivery platform based on LPC-bound EPA and DHA from krill, alongside INVI, a hydrolyzed protein isolate suitable for food and beverage applications. Beyond its core ingredient business, the company distributes natural supplements and various human health and nutrition products. Furthermore, it oversees AION, a circular solutions provider focused on waste recycling and material reuse.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITD.
Target Price
The average target price of AKBM.OL is 120 and suggests 3.6% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to